A patient-oriented approach to treatment of myelodysplastic syndromes

Haematologica

Volumn 83, Issue 10, 1998, Pages 910-935

  Cazzola, Mario ^a,e   Anderson, Jeanne E ^b   Ganser, Arnold ^c   Hellström Lindberg, Eva ^d  

^a UNIVERSITY OF PAVIA   (Italy)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Myelodysplastic syndromes; Therapy

Indexed keywords

ACLARUBICIN; ALPHA INTERFERON; AMIFOSTINE; ANDROGEN; AZACITIDINE; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DANAZOL; DAUNORUBICIN; DEFEROXAMINE; ETOPOSIDE; FLUDARABINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; HOMOHARRINGTONINE; IDARUBICIN; INTERLEUKIN 3; INTERLEUKIN 6; ISOTRETINOIN; MITOXANTRONE; PYRIDOXINE; RECOMBINANT ERYTHROPOIETIN; RETINOIC ACID; TIOGUANINE; UNINDEXED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOTRANSPLANTATION; BLOOD TRANSFUSION; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONSERVATIVE TREATMENT; CYTOGENETICS; DECISION MAKING; DOSE RESPONSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA REMISSION; MYELODYSPLASTIC SYNDROME; PATIENT CARE; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW;

EID: 0031762071     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (220)

1. Gallagher A, Darley RL, Padua R. The molecular basis of myelodysplastic syndromes. Haematologica 1997; 82:191-204.
2. Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 1998; 83:71-86.
3. Vallespi T, Imbert M, Mecucci C, Preudhomme C, Fenaux P. Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Haematologica 1998; 83:258-75.
4. Sanz GF, Sanz MA, Grenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 1998 ; 83:358-68.
5. Locatelli F, Zecca M, Pession A, Maserati E, De Stefano P, Severi F. Myelodysplastic syndromes: the pediatric point of view. Haematologica 1995; 80: 268-79.
6. Delforge M, Demuynck H, Vandenberghe P, et al. Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood 1995; 86:3660-7.
7. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079-88.
8. Cazzola M, Riccardi A. Myelodysplastic syndromes: biologic and clinical aspects. Haematologica 1986; 71:147-54.
9. Cotter PD, May A, Fitzsimons EJ, et al. Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid δ-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts. J Clin Invest 1995; 96:2090-6.
10. May A, Bishop DF. The molecular biology and pyridoxine responsiveness of X-linked sideroblastic anemia. Haematologica 1998; 83:56-70.
11. Riccardi A, Giordano M, Girino M, et al. Refractory cytopenias: clinical course according to bone marrow cytology and cellularity. Blut 1987; 54:153-63
12. Kobaba R, Kanamaru A, Takemoto Y, Kohsaki M, Kakishita E, Nagai K. Androgen in the treatment of refractory anemia. Int J Hematol 1991; 54:103-7
13. Bagby GC Jr, Gabourel JD, Linman JW. Glucocorticoid therapy in the preleukemic syndrome (hemopoietic dysplasia): identification of the responsive patients using in-vitro techniques. Ann Intern Med 1980; 92:55-8.
14. Cines DB, Cassileth PA, Kiss JE. Danazol therapy in myelodysplasia. Ann Intern Med 1985; 103:58-60.
15. Chabannon C, Molina L, Pegourie-Bandelier B, Bost M, Leger J, Hollard D. A review of 76 patients with myelodysplastic syndromes treated with danazol. Cancer 1994; 73:3073-80.
16. Finch CA, Huebers HA. Perspectives in iron metabolism. N Engl J Med 1982; 306:1520-8.
17. Schafer AI, Rabinowe S, Le Boff MS, Bridges K, Cheron RG, Dluhy R. Long-term efficacy of desferoxamine iron chelation therapy in adults with acquired transfusional iron overload. Arch Intern Med 1985; 145:1217-21.
18. Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94:288-99.
19. Del Rio Garma J, Fernandez Lago C, Batlle Fonrodona FJ. Desferrioxamine in the treatment of myelodysplastic syndromes. Haematologica 1997; 82:639-40.
20. Al Refaie FN, Hershko C, Hoffbrand AV, et al. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995; 91:224-9.
21. Kersten MJ, Lange R, Smeets ME, et al. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Ann Hematol 1996; 73:247-52.
22. Yoshida Y, Hirashima K, Asano S, et al. Phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol 1991; 78:378-84.
23. Negrin RS, Haeuber DH, Nagler A, et al. Treatment of myelodysplastic syndromes with recombinant human granulocyce colony-stimulating factor. A phase I-II trial. Ann Intern Med 1989;110:976-84.
24. Negrin RS, Haeuber DH, Nagler A, et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 1990; 76:36-43.
25. Greenberg P, Taylor K, Larson R, et al. Phase III randomized multicenter trial of G-CSF vs observation for MDS [abstract]. Blood 1993; 82 (Suppl 1): 196a.
26. Rebulla P, Finazzi G, Marangoni F, et al. A multicenter randomized study of the threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997; 337:1870-5.
27. Morosetti R, Koeffler HP. Differentiation therapy in myelodysplastic syndromes. Semin Hematol 1996; 3:236-45.
28. Gold EJ, Mertelsmann RH, Itri LM, et al. Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes. Cancer Treat Rep 1983; 67:981-6.
29. Greenberg BR, Durie BG, Garnett TC, et al. Phase I-II study of 13-cis-retinoic acid in myelodysplastic syndrome. Cancer Treat Rep 1985; 69:1369-74.
30. Swanson GF, Picozzi VJ, Morgan R, et al. Response of hematopoietic precursors to 13-cis-retinoic acid and 1,25 dihydroxyvitamin D3 in myelodysplastic syndromes. Blood 1986; 67:1154-61.
31. Picozzi VJ, Swanson GF, Morgan R, et al. 13-cis-retinoic acid treatment for myelodysplastic syndromes. J Clin Oncol 1986; 4:589-95.
32. Kerndrup G, Benedix-Hansen K, Pedersen B, et al. 13-cis-retinoic acid treatment of myelodysplastic syndromes. Leuk Res 1987; 11:7-16.
33. Clark RE, Ismail SA, Jacobs A, et al. A randomized trial of 13-cis-retinoic acid with or without cytosine arabinoside in patients with myelodysplastic syndromes. Br J Haematol 1987; 66:77-83.
34. Leoni F, Ciolli S, Longo G, et al. 13-cis-retinoic acid treatment in patients with myelodysplastic syndrome. Acta Haematologica 1988; 80:8-12.
35. Koeffler HP, Heitjan D, Mertelsmann R, et al. Randomized study of 13-cis retinoic acid versus placebo in the myelodysplastic disorders. Blood 1988; 71:703-8.
36. Hast R, Lauren SAL, Reizenstain P. Absent clinical effect of retinoic acid and isotreinoin treatment in the myelodysplastic syndrome. Hematol Oncol 1989; 7:297-301.
37. Besa EC, Abrahm JL, Bartholomew MJ, et al. Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and dereased toxicity with addition of α-tocopherol. Am J Med 1990; 89:739-47.
38. Bourantas KL, Tsiara S, Christou L. Treatment of 34 patients with myelodysplastic syndromes with 13-cis retinoic acid. Eur J Haematol 1995; 55:235-9.
39. Visani G, Cenacchi A, Tosi P, et al. All-trans retinoic acid improves erythropoiesis in myelodysplasic syndromes: A case report. Br J Haematol 1992; 81:444-56.
40. Ohno R, Naoe T, Hirano M, et al. Treatment of myelodysplastic syndromes with all-trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare. Blood 1993; 81:1152-4.
41. Aul C, Runde V, Gattermann N. All-trans retinoic acid in patients with myelodysplastic syndromes: Results of a pilot study. Blood 1993; 82:2967-74.
42. Kurzrock R, Estey E, Talpaz M. All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. J Clin Oncol 1993; 11:1489-95.
43. Baldus M, Walter H, Möller M, Schurfeld C, Brass H. All-trans retinoic acid (ATRA) in the treatment of myelodysplastic syndromes. Results in 5 cases. Onkologie 1994; 17:515-20.
44. Cambier N, Wattel E, Menot ML, Guerci A, Chomienne C, Fenaux P. All-trans retinoic acid in adult chronic myelomonocytic leukemia. Results of a pilot study. Leukemia 1996; 10:1164-7.
45. Ganser A, Seipelt G, Verbeek W, et al. Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes. Leukemia 1994; 8:369-75.
46. Ganser A, Maurer A, Contzen C, et al. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and α-tocopherol. Ann Hematol 1996; 72:237-44.
47. Metha AB, Kumaran TO, Marsh GW. Treatment of myelodysplastic syndrome with α-calcidol [letter]. Lancet 1984; 2:761.
48. Koeffler HP, Hirji K, Itri L, et al. 1,25-dihydroxyvitamin D3: In vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 1985; 69:1399-407.
49. Richard C, Mazo E, Cuadrado MA, et al. Treatment of myelodysplastic syndrome with 1,25-dihydroxyvitamin D3. Am J Hematol 1986; 73:175-8.
50. Motomura S, Kanamori H, Maruta A, Kodama F, Ohkubo T. The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. Am J Hematol 1991; 38:67-8.
51. Hellström E, Robert KH, Samuelsson J, et al. Treatment of myelodysplastic syndromes with retinoic acid and 1α-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. Eur J Haematol 1990; 45:255-61.
52. Ferrero D, Bruno B, Pregno P, et al. Combined differentiating therapy for myelodysplastic syndromes. A phase II study. Leukemia Res 1996; 20:867-76.
53. Elias L, Hoffman R, Boswell S, et al. A trial of recombinant α2 interferon in the myelodysplastic syndromes: I. Clinical results. Leukemia 1987; 1:105-10.
54. Galvani DW, Nethersell AB, Cawley JC. Alpha-interferon in myelodysplasia; clinical observations and effects on NK cells. Leuk Res 1988;12:257-62.
55. Catalano L, Majolino I, Pellegrino M, et al. α-interferon in the treatment of chronic myelomonocytic leukemia. Haematologica 1989; 74:577-81.
56. Gisslinger H, Chott A, Linkesch W, et al. Long-term α-interferon therapy in myelodysplastic syndromes. Leukemia 1990; 4:91-4.
57. Holcombe RF. Mini-dose interferon α-2a in the treatment of myelodysplasia. Leukemia 1993;7:192-5.
58. Petti MC, Latagliata R, Avvisati G, et al. Treatment of high-risk myelodysplastic syndromes with lymphoblastoid α interferon. Br J Haematol 1996; 95:364-7.
59. Hellstrom E, Robert KH, Gahrton G, et al. Therapeutic effect of low-dose cytosine arabinoside alpha-interferon, 1α-hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes. Eur J Haematol 1988; 40:449-59.
60. Schwarzinger I, Stain C, Bettelheim P, et al. Gamma-interferon in myelodysplastic syndromes: A pilot study. Oncology 1990; 47:322-6.
61. Maiolo At, Cortelazzi A, Calori R, et al. Recombinant γ-interferon as first line therapy for high risk myelodysplastic syndromes. Leukemia 1990; 4:480-5.
62. Stone RM, Spriggs DR, Arthur KA, Mayer RJ, Griffin J, Kufe DW. Recombinant human γ interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes. Am J Clin Oncol Cancer Clin Trials 1993; 16:159-63.
63. Rowinsky EK, Conley BA, Jones RJ, et al. Hexamethylene bisacetamide in myelodysplastic syndrome: Effect of five-day exposure to maximal therapeutic concentrations. Leukemia 1992; 6:526-34.
64. Andreeff M, Stone R, Michaeli J, et al. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 1992; 80:2604-9.
65. Silverman LR, Davis RB, Holland JF, et al. 5-Azacytidine (AZ) as a low-dose continuous infusion is an effective therapy for patients with myelodysplastic syndromes (MDS). Blood 1989; 73:263-70.
66. Chitambar CR, Libnoch JA, Matthaeus WG, Ash RC, Ritch PS, Anderson T. Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. Am J Hematol 1991; 37:100-4.
67. Wijermans PW, Krulder JWM, Huijgens PC, Neve P. Continuous infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997; 11 (Suppl 1):S19-S23.
68. Zagonel V, Lo Re G, Marotta G, et al. 5-Aza-2′-doxycytidine (Decitabine) induces trinlineage response in unfavorable myelodysplastic syndromes. Leukema 1993; 7:30-5.
69. Feldman EJ, Seiter KP, Ahmed T, Baskind P, Arlin ZA. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia 1995; 10:40-2.
70. Ho AD, Martin H, Knauf W, Reichardt P, Trumper L, Hunstein W. Combination of low-dose cytarabine and 13-cis retinoic acid in the treatment of myelodysplastic syndromes. Leuk Res 1987;11:1041-4.
71. Maurer AB, Ganser A, Seipelt G, et al. Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haemopoietic growth factors. Br J Haematol 1995; 89:449-56.
72. List AF, Brasfield F, Heaton R, et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 1997; 90:3364-9.
73. Cazzola M, Mercuriali F, Brugnara C. Clinical use of recombinant human erythropoietin outside the setting of uremia. Blood 1997; 89:4248-67.
74. Stenke L, Wallvik J, Celsing F, Hast R. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. Leukemia 1993; 7:1324-7.
75. Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89:67-71.
76. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 1995; 89:831-7.
77. Cazzola M, Guarnone R, Cerani P, Centenara E, Rovati A, Beguin Y. Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood 1998; 91:2139-45.
78. Aloe Spiriti MA, Latagliata R, Petti MC. Erythropoietin in myelodysplastic syndromes: durable response in a young patient [letter]. Haematologica 1996; 81:381-2.
79. Vadhan-Raj S, Keating M, LeMaistre A, et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl Med 1987; 317:1545-52.
80. Thompson JA, Lee DJ, Kidd P, et al. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. J Clin Oncol 1989; 7:629-37.
81. Estey EH, Kurzrock R, Talpaz M, et al. Effects of low doses of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Br J Haematol 1991; 77:291-5.
82. Willemze R, van der Lely N, Zwierzina H, et al. A randomised phase I-II multicenter study of granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. Ann Hematol 1992; 64:173-80.
83. Rose C, Wattel E, Bastion Y, et al. Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 cases. Leukemia 1994; 8:1458-62.
84. Shuster MW, Larson RA, Thompson JA, Coiffier B, Bennett JM, Israeil RJ. Granulocyte-macrophage colony-stimulating factor (GM-CSF) for myelodysplastic syndrome: Results of a multi-center randomized controlled trial [abstract]. Blood 1990; 76 (Suppl 1):318a.
85. Shuster MW, Thompson JA, Larson B, Coiffier B, Bennett J, Dugan M. Randomized phase II study of recombinant human granulocyte-macrophage colony-stimulating factor (rGM-CSF) in patients with neutropenia secondary to myelodysplastic syndromes [abstract]. Blood 1995; 86 (Suppl 1):338a.
86. Yoshida Y, Nakahata T, Shibata A, et al. Effects of long-term treatment with recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. Leuk Lymphoma 1995; 5-6:457-63.
87. Yoshida Y, Hirashima K, Asano S, Takaku F. A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol 1991; 78:378-84.
88. Ganser A, Seipelt G, Lindemann A, et al. Effects of recombinant human interleukin 3 in patients with myelodysplastic syndromes. Blood 1990; 76:455-62.
89. Nimer SD, Raquette RL, Ireland P, Resta D, Young D, Golde DW. A phase I-II study of interleukin-3 in patients with aplastic anemia and myelodysplasia. Exp Hematol 1994; 22:875-80.
90. Hand S, Sosman J, Godwin JE, Fisher RI. A phase I-II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes. Blood 1994; 83: 357-60.
91. Gordon MS, Nemunaitis J, Hoffman R, et al. A phase I-II trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 1995; 85: 3066-76.
92. Negrin RS., Stein R, Doherty K, et al. Treatment of the anemia of myelodysplastic syndromes using human granulocyte-CSF in combination with erythropoietin. Blood 1993; 82: 737-43.
93. Hellström-Lindberg E, Birgegård G, Carlsson M, et al. A combination of granulocyte-colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lyrnphoma 1993; 11: 221-8.
94. Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996; 87: 4076-81.
95. Hellström-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of the anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998; 92:68-75.
96. Bessho M, Jinnai I, Hirashima K, et al. Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia. Stem Cells 1994; 12:604-15.
97. Imamura M, Kobayashi M, Kobayashi S, et al. Failure of combination therapy with granulocyte colony-stimulating factor and erythropoietin in myelodysplastic syndromes. Ann Hematol 1994; 68: 163-6.
98. Musto P, Falvone A, Carotenuto M. Granulocyte colony-stimulating factor and erythropoietin for the anemia of myelodysplastic syndromes: A real improvement with respect to EPO alone? Blood 1994; 84: 1687-88.
99. Ganser A, Maurer A, Contzen C, et al. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and aipha-tocopherol. Ann Hematol 1996; 72: 237-44.
100. Hellström-Lindberg E, Negrin R, Stein R, et al. Erytbroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997; 99:344-51
101. Hansen PB, Johnsen H, Hippe E, Hellström-Lindberg E, Ralfkiaer E. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplasia. Am J Hematol 1993; 44: 229-36.
102. Runde V, Aul C, Ebert A, Grabenhorst U, Schneider W. Sequential administration of recombinant human granulocyte-macrophage colony-stimulating factor and human erythropoietin for treatment of myelodysplastic syndromes. Eur J Haematol 1995; 54:39-45.
103. Bernell P, Stenke L, Wallvik J, Hippe E, Hast R. A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes. Leuk Res 1996; 20: 693-9.
104. Musto P, Scalzulii P, De Santis R, Coscarella A, Novelli S, Carotenuto M. Recombinant erythropoietin (EPO) and GM-CSF for the anaemia of myelodysplastic syndromes (MDS): in vivo effects and preliminary in vitro results of a hybrid (GM-CSF/EPO) molecule (MEN 11300) [abstract]. Br J Haematol 1996; 93 (Suppl 2): 66.
105. Thompson J, Gilliland G, Prchal J, et al. The use of GM-C5F±r-HuEpo for the treatment of cytopenias associated with myelodysplastic syndromes. Blood 1995; 86(Suppl 1):167a.
106. List AL, Noyes W, Power J, et al. Combined treatment of myelodysplastic syndromes (MDS) with recombinant human interleukin 3 and erythropoietin (EPO). Blood 1994; 84 (Suppl 1):377a.
107. Verhoef G, Demuynck H, Zacheé P, Ceuppens J, De Witte M, Boogaerts M. Treatment of myelodysplastic syndromes (MDS) with the combination of interleukin 3 and erythropoietin. Blood 1994; 84 (Suppl 1):377a.
108. Baccarani M, Tura S. Differentiation of myeloid leukemic cells: new possibilities for therapy. Br J Haematol 1979; 42: 485-7.
109. Housset M, Daniel MT, Degos L. Small doses of ara-C in the treatment of acute myeloid leukemia: differentiation of myeloid leukemia cells? Br J Haematol 1982; 51: 125-9.
110. Baccarani M, Tazzari PL, Motta MR, Rizzi S, et al. Cell kinetic effect of low-dose arabinosylcytosine. Br J Haematol 1987; 67:33-7.
111. Hossfeld DK, Weh HJ, Kleeberg UR. Low-dose cytarabine: chromosomal findings suggesting its cytostatic as well as differentiating effect. Leuk Res 1985; 9:329-30.
112. Vial JP, Belloc F, Dumain P, et al. Study of the apoptosis induced in vitro by antiturnoral drugs on leukaemic cells. Leuk Res 1996; 21: 163-72.
113. Castaigne S, Daniel MT, Tilly H, Herait P, Degos L. Does treatment with ara-C in low dosage cause differentiation of leukemic cells? Blood 1983; 62: 85-6.
114. Aul C, Schneider W. The role of low-dose cytosine ara-binoside and aggressive chemotherapy in advanced myelodysplastic syndromes. Cancer 1989; 64:1812-8.
115. Tricot G, Bock R de, Dekker AW, Boogaerts MA, Peetermans M, Punt K, Verwilghen RL. Low dose cytosine arabinoside (Ara-C) in myelodysplastic syndromes. Br J Haematol 1984; 58: 231-40.
116. Powell BL, Capizzi RL, Jackson DV, et al. Low dose ara-C for patients with myelodysplastic syndromes. Leukemia 1988; 2: 153-6.
117. Griffin JD, Spriggs D, Wisch JS, Kufe DW. Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside. J Clin Oncol 1985; 3:982-91.
118. Pesce A, Cassuto JP, Bayle J, et al. Very-low dose cytarabine for elderly patients. Lancet 1986; i:1436.
119. Cheson BD, Simon R. Low-dose ara-C in acute non-lymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience. Semin Oncol 1987; 14(2 Suppl 1):126-33.
120. Hellström-Lindberg E, Robért KH, Gahrton G, et al. A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukemia. Br J Haematol 1992; 81:503-11.
121. Miller KB, Kyungman K, Morrison FS, et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase III intergroup study. Ann Hematol 1992; 65: 162-8.
122. Cannistra SA, Groshek P, Griffin JD. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effect of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 1989; 3:328-34.
123. Economopoulos T, Papageorgiou T, Stathakis N, et al. Treatment of myelodysplastic syndromes with human granulocyte-macrophage colony-stimulating factor (GM-CSF) or CM-CSF combined with low-dose cytosine arabinoside. Eur J Haematol 1992; 48: 138-42.
124. Gerhartz HH, Marcus R, Delmar A, et al. A randomized phase H study of low-dose cytosine arabinoside (LD-araC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. Leukemia 1994; 8:16-23.
125. Gerhartz HH, Walther J, Neuwirtova R, et al. Randomized 3-armed phase III study of interleukin 3 (IL-3) or granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjuvant to low-doses of cytosine arabinoside (LD-AraC) for the treatment of high risk myelodysplastic syndromes. Blood 1996; 88 (Suppl 1); 580a.
126. Im T, Yamane T, Mugitani A, Hiyoshi M, Park K, Tatsumi N. Treatment with cytosine arabinoside and granulocyte colony-stimulating factor in patients with myelodysplastic syndrome and its leukemic phase. Int J Hematol 1994; 60: 215-23.
127. Shibuya T, Teshima T, Harada M et al. Treatment of myelodysplastic syndrome and atypical leukemia with low-dose aclarubicin. Leuk Res 1990; 14: 161-7.
128. Harada M, Shibuya T, Teshila T et al. A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes. Leuk Res 1993; 17:629-32.
129. Johnson E, Parapia LA. Successful oral chemotherapy with idarubicin in refractory anaemia with excess blasts. Eur J Haematol 1987; 39:278-81.
130. Lowenthal RM, Lambertenghi-Deliliers G. Oral idarubicin as treatment for advanced myelodysplastic syndromes. Haematologica 1991; 76:398-401.
131. Greenberg BR, Reynolds RD, Charron CB, et al. Treatment of myelodysplastic syndromes with oral idarubicin. Cancer 1993; 71: 1989-92.
132. Omoto E, Deguchi S, Takaba S, Kojima K, Yano T, KatayamaY, Sunami K, Takeuchi M, Kimura F, Harada M, Kimura I. Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. Leukemia 1996; 10:609-14.
133. Oscier D, Worsley A, Hamblin T, Mufti G. Treatment of chronic myelomonocytic leukemia with low-dose etoposide. Br J Haematol 1989; 72: 468-71.
134. Wattel E, Guerci A, Hecquet B, et al. A randomized trial of hydroxyurea versus VP 16 in adult chronic myelomonocytic leukemia. Blood 1996; 88:2480-7.
135. Cheson BD. Chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Semin Ortcol 1992; 19:85-94.
136. Gassmann W, Schmitz N, Löffler H, De Witte T. Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Semin Hematol 1996; 33:196-205.
137. Mertelsmann R, Thaler HT, To L, et al. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 1980; 56:773-81.
138. Keating MJ, Mc Credie KB, Benjamin RS, et al. Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP). Blood 1981; 58:584-91.
139. Fenaux P, Lai JL, Jouet JP, et al. Aggressive chemotherapy in adult primary myelodysplastic syndromes. Blut 1988; 57:297-302.
140. Martiat P, Ferrant A, Michaux JL, Sokal G. Intensive chemotherapy for acute non-lymphoblastic leukemia after primary myelodysplastic syndrome. Haematol Oncol 1988; 6:299-305.
141. Michels SD, Saumur J, Arthur DC, Robison LL, Brunning RD. Refractory anemia with excess of blasts in transformation hematological and clinical study of 52 patients. Cancer 1989; 64:2340-6.
142. Gajewski JL, Ho WG, Nimer SD, et al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol 1989; 7:1637-45.
143. Hoyle CF, De Bastos M, Wheatley K, et al. AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. Br J Haematol 1989; 72:45-53.
144. De Witte T, Muus P, De Pauw B, et al. Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukaemia youger than 65 years. Bone Marrow Transplant 1989; 4 (Suppl 3):33-5.
145. Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 1991; 77:497-501.
146. Knauf WU, Berdel WE, Ho AD, et al. Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia. Leuk Lymphoma 1994; 12:421-5.
147. Wattel E, Solary E, Caillot D, et al. Intensive chemotherapy (CT) with or without quinine followed by autologous BMT in myelodysplastic syndromes (MDS) and secondary leukemia (SL). Preliminary results of a randomized trial [abstract]. Blood 1995; 86 (Suppl 1):804a.
148. De Witte T, Suciu S, Peetermans M, et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia 1995; 9:1805-1811.
149. De Witte T, Suciu S, Boogaerts M, et al. Intensive remission-induction chemotherapy followed by autologous or allogeneic stem cell transplantation (SCT) for high risk MDS and AML secondary to MDS (sAML) in patients < 60 years. A joint study of the EORTC LCG and the EBMT [abstract]. Blood 1995; 86 (Suppl 1):618a.
150. Aul C, Runde V, Germing U, Burk M, Heyll A, Hildebrandt B, Willers R: Remission rates, survival and prognostic factors in 94 patients with advanced MDS treated with intensive chemotherapy [abstract]. Ann Haematol 1995; 70(suppl. II):A138.
151. Bernasconi C, Alessandrino EP, Bernasconi P, et al. Randomised clinical study comparing aggressive chemotherapy with or without G-CFS support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS. Br J Haematol 1998; 102:678-83.
152. Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994; 12:671-8.
153. Gore SD, Burke PJ. Long-term survival of subsets of patients with advanced myelodysplastic syndromes (MDS) treated with intensive chemotherapy [abstract]. Blood 1995; 86 (Suppl 1):339a.
154. Ossenkoppele GJ, Verhoef GEG, Verfoef GEG, et al. Randomized Phase II study on the value of G-CSF (filgrastim) in combination with standard induction chemotherapy in myelodysplastic syndromes (MDS) [abstract]. Blood 1995; 86 (Suppf 1):338a.
155. Ganser A, Heil G, Hofmann WK, et al. Aggressive chemotherapy with idarubicin, ara-C, VP-16, amsacrin, followed by G-CSF and maintenance immunotherapy with interleukin-2 for advanced myelodysplastic syndromes and high-risk ANLL. Blood 1995; 86 (Suppl 1):434a.
156. Steinmetz HT, Staib P, Glasmacher A, et al. Phase II study of idarubicin, fludarabine, ara-C, and G-CSF (Ida-FLAG) for treatment of refractory, relapsed and secondary acute myeloid leukemia [abstract]. Br J Haematol 1996; 93 (Suppl 2):219.
157. Gardin C, Chaibi P, de Revel T, et al. Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Leukemia 1997; 11:16-21.
158. Estey E, Peter Beran TM, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 1997; 90:2969-77.
159. Invernizzi R, Pecci A, Rossi G, et al. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes. Haematologica 1997; 82:660-3.
160. Ruutu T, Hänninen A, Järventie G, et al. Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine. Leuk Res 1997; 21:133-8.
161. Lepelley P, Soenen V, Preudhomme C, Lai JL, Cosson A, Fenaux P. Expression of the multidrug resistance P glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia 1994; 8:998-1005.
162. Demuynck H, Delforge M, Verhoef GEG, et al. Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. Br J Haematol 1996; 92:351-9.
163. Mattijssen V, Schattenberg A, Schaap N, Preijers F, De Witte T. Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes. Bone Marrow Transplant 1997; 19:791-4.
164. Locatelli F, Niemeyer C, Angelucci E, et al. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol 1997; 15:566-73.
165. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for refractory anemia: A comparison of two preparative regimens and analysis of prognostic factors. Blood 1996; 87:51-8.
166. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14:220-6.
167. Demuynck H, Verhoef GE, Zachee P, et al. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. Bone Marrow Transplant 1996; 17:745-51.
168. Sutton L, Chastang C, Ribaud P, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societé Française de Greffe de Moelle. Blood 1996; 88:358-65.
169. O'Donnell MR, Long GD, Parker PM, et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 1995; 13:2973-9.
170. Anderson JE, Appelbaum FR, Fisher LD, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993; 82: 677-81.
171. Ratanatharathorn V, Karanes C, Uberti J, et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 1993; 81:2194-9.
172. Nevill TJ, Shepherd JD, Reece DE, et al. Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant 1992; 10:445-50.
173. DeWitte T, Zwaan F, Hermans J, et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 1990; 74:151-5.
174. Longmore G, Guinan EC, Weinstein HJ, Gelber RD, Rappeport JM, Antin JH. Bone marrow transplantation for myelodysplasia and secondary acute non-lymphoblastic leukemia. J Clin Oncol 1990; 8:1707-14.
175. Anderson JE, Thomas ED. The Seattle experience with bone marrow transplantation (BMT) for myelodysplasia (MDS) [abstract]. Leuk Res 1997; 21 (Suppl 1):S51.
176. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51:189-99.
177. Anderson JE, Appelbaum FR, Storb R. An update on allogeneic marrow transplantation for myelodysplastic syndrome. Leuk Lymphoma 1995; 17:95-9.
178. Morel P, Hebbar M, Lai J-L, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993; 7:1315-23.
179. Cazzola M, Ponchio L, Rosti V, Farina G, Pedrotti C, Bergamaschi G. Diagnostic approach to the myelodysplastic syndromes. Leukemia 1992; 6(suppl. 4):19-22.
180. Appelbaum FR, Barrall J, Storb R, et al. Bone marrow transplantation for patients with myelodysplasia. Ann Intern Med 1990; 112:590.
181. De Witte T, Hermans J, van Biezen A, et al. Prognostic variables in bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes: a survey of the working party on leukaemia. Bone Marrow Transplant 1991; 7 (Suppl 2):40.
182. Sierra J, Carreras E, Rozman C, Champlin R, Rowlings P, Horowitz M. Bone marrow transplantation for myelodysplasia: the IBMTR data [abstract]. Leuk Res 1997; 21 (Suppl 1):S51.
183. Anderson JE, Anasetti C, Appelbaum FR, et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol 1996; 93:59-67.
184. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328:593-602.
185. Arnold R, De Witte T, van Biezen A, et al. MUD BMT in MDS/sAML: an EBMT survey [abstract]. Blood. 1995; 86 (Suppl 1):95a.
186. Davies SM, Wagner JE, Defor T, et al. Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia or myelodysplasia. Br J Haematol 1997; 96:749-56.
187. Casper J, Camitta B, Truitt R, et al. Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. Blood 1995; 85:2354-63.
188. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995; 86:3542-52.
189. Stone RM. Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress? Blood 1994; 83:3437-40.
190. Anderson JE, Gooley TA, Schoch G, et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997; 89:2578-85.
191. Ballen KK, Gilliland DG, Guinan EC, et al. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia [abstract]. Blood 1995; 86 (Suppl 1):95a
192. Le Maignan C, Ribaud P, Maraninchi D, et al. Bone marrow transplantation for mutagen-related leukemia or myelodysplasia[abstract]. Exper Hematol 1990; 18:660.
193. Bandini G, Rosti G, Calori E, Albertazzi L, Tura S. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome. Br J Haematol 1990; 75:442-3.
194. De Witte T. Response to allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome. Br J Haematol 1990; 75:443-4.
195. Bunin NJ, Casper JT, Chitambar C, et al. Partially matched bone marrow transplantation in patients with myelodysplastic syndromes. J Clin Oncol 1988; 6:1851-5.
196. Alessandrino EP, Astori C, Van Lint MT, et al. Myelodysplastic syndrome or leukemia developing after MDS treated by allogeneic bone marrow transplantation: outcome of 90 adult patients [abstract]. Leuk Res 1997; 21 (Suppl 1):S52.
197. Matthews DC, Appelbaum FR, Eary JF, et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1995; 85:1122-31.
198. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86:2041-50.
199. Tsuzuki M, Maruyama F, Kojima H, Ezaki K, Hirano M. Donor buffy coat infusions for a patient with myelodysplastic syndrome who relapsed following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 16:487-9.
200. Okumura H, Takamatsu H, Yoshida T. Donor leucocyte transfusions for relapse in myelodyplastic syndrome after allogeneic bone marrow transplantation. Br J Haematol 1996; 93:386-8.
201. Bressoud A, Chapuis B, Roux E, et al. Donor lymphocyte infusion for a patient with relapsing myelodysplastic syndrome after allogeneic bone marrow transplantation. Blood 1996; 88:1902-3.
202. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15:433-44.
203. Porter DL, Roth MS, Lee SJ, McGarigle C, Ferrara JLM, Antin JH. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 18:975-80.
204. Castro-Malaspina H, Childs B, Papadopoulos E, et al. T-cell depleted (SBA-E-) bone marrow transplantation for myelodysplastic syndromes [abstract]. Leuk Res 1997; 21 (Suppl 1):S51.
205. Culligan DJ, Bowen DT, May A, White D, Padua RA, Burnett AK. Refractory anaemia with preleukaemic polyclonal haemopoiesis and the emergence of monoclonal erythropoiesis on disease progression. Br J Haematol 1995; 89:675-77.
206. Ito T, Ohashi H, Kagami Y, Ichikawa A, Saito H, Hotta T. Recovery of polyclonal hematopoiesis in patients with myelodysplastic syndromes following successful chemotherapy. Leukemia 1994; 8:839-43.
207. Carella AM, Dejana A, Lerma E, et al. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. Br J Haematol 1996; 95:127-30.
208. De Witte T, Van Biezen A, Hermans J, et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Blood 1997; 90; 3853-7.
209. Wattel E, Solary E, Caillot D, et al. Autologous bone marrow (ABMT) or peripheral blood stem cell (ABSCT) transplantation after intensive chemotherapy in myelodysplastic syndromes (MDS) [abstract]. Leuk Res 1997; 21 (Suppl 1):S52.
210. Oberg G, Simonsson B, Smedmyr B, et al. Is haematological reconstitution seen after ABMT in MDS patients? [abstract]. Bone Marrow Transplant 1989; 4 (Suppl 2):52.
211. Laporte JP, Isnard F, Lesage S, et al. Autologous bone marrow transplantation with marrow purged by mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): a pilot study. Leukemia 1993; 7:2030-33.
212. Anonymous. Towards an increasingly molecular-based, patient-oriented treatment of acute myeloid leukemia. Haematologica 1996; 81:1-2.
213. Aglietta M, De Vincentiis A, Lanata L, et al. Peripheral blood stem cells in acute myeloid leukemia: biology and clinical applications. Haematologica 1996; 81:77-92.
214. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997; 99:699-705.
215. Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer 1997; 79:1548-51.
216. Delforge M, Demuynck H, Verhoef G, et al. Patients with high-risk myelodysplastic syndrome can have polydonal or clonal haemopoiesis in complete haematological remission. Br J Haematol 1998; 102:486-94.
217. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985; 59:425-33.
218. Sanz GF, Sanz MA, Vallespí T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74:395-408.
219. Goasguen JE, Gerard R, Bizet M, et al. Prognostic factors of myelodysplastic syndromes - a simplified 3-D scoring system. Leuk Res 1990; 14:255-62.
220. Morra E, Lazzarino M, Castello A, et al. Risk assessment in myelodysplastic syndromes: value of clinical, hematologic and bone marrow histologic findings at presentation. Eur J Haematol 1990; 45:94-8.